BeiGene Clinical Trial Pipeline — 39 Active Studies

Phase 1: 11, Phase 2: 18, Phase 3: 8, Other: 2

BeiGene has emerged as one of the most significant oncology-focused biopharmaceuticals globally, with particular strength in B-cell malignancies and solid tumor targeted therapy. Brukinsa (zanubrutinib) is a next-generation covalent BTK inhibitor with superior CNS penetration and more complete BTK occupancy than first-generation ibrutinib — it has become one of the fastest-growing hematology drugs globally, with approvals across CLL/SLL, Waldenström's macroglobulinemia, mantle cell lymphoma, and marginal zone lymphoma. Tislelizumab, their PD-1 checkpoint inhibitor, is approved in multiple indications in China and is advancing through global registrations. BeiGene's solid tumor pipeline includes a KRAS G12C inhibitor and multiple investigational combinations across gastrointestinal and thoracic malignancies.

• Hematology (CLL, MCL, WM, marginal zone lymphoma)
• BTK inhibition (B-cell malignancies)
• Solid tumors (PD-1, KRAS G12C, TIGIT)
• Gastrointestinal oncology
• Global clinical development (China + international)

• Brukinsa (zanubrutinib) — next-gen BTK, CLL/SLL/MCL/WM
• Tislelizumab — PD-1, multiple solid tumors and hematology
• BGB-10188 — PI3Kδ inhibitor, B-cell malignancies
• BGB-3245 — BRAF inhibitor, RAF-altered cancers
• Sonrotoclax — BCL-2 inhibitor, hematologic malignancies
• BGB-A445 — OX40 agonist, solid tumors

BeiGene's Brukinsa (zanubrutinib) continues expanding its CLL and MCL label — combination trials with BCL-2 inhibitors (sonrotoclax) and CD20 antibodies are among the most actively followed in hematology BD. Their BCL-2 inhibitor sonrotoclax is a direct competitor to venetoclax, making BeiGene's trial registrations critical competitive intelligence for Roche and AbbVie.

DataLookout monitors ClinicalTrials.gov daily and surfaces changes to BeiGene's registered studies: new trial registrations, status transitions (for example "Not yet recruiting" to "Recruiting"), site additions, and protocol amendments. This is the intelligence layer that bridges the gap between quarterly investor calls and day-to-day pipeline developments.

• Sponsor normalization: BeiGene may register trials under multiple legal entity names. DataLookout normalizes all related entities to a single canonical sponsor for complete pipeline coverage.
• Daily updates: ClinicalTrials.gov is queried each morning. New registrations and updates appear in that day's digest.
• Field-level change detection: Status changes, enrollment updates, and site additions are detected and surfaced, not just new registrations.
• Phase filtering: Focus on Phase 3 pivotal trials, Phase 2 proof-of-concept studies, or all phases for comprehensive coverage.
• Indication filtering: Combine sponsor monitoring with indication keywords to focus on the therapeutic areas relevant to your business.